PR
KYMR icon

PSP Research’s Kymera Therapeutics KYMR Stock Holding History

PSP Research’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Sell
4,000
-2,300
-37% -$198K 0.24% 26
2026
Q1 		$525K Sell
6,300
-48
-0.8% -$3.8K 0.37% 10
2025
Q4 		$494K Buy
+6,348
New +$429K 0.43% 77

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PSP Research's KYMR Position: Q2 2026 in Review

PSP Research reduced its Kymera Therapeutics (KYMR) stake by 37% in Q2 2026, selling an estimated $198K and leaving 4,000 shares worth $459K. The position accounts for 0.24% of the portfolio, ranked #26.

PSP Research first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. The position peaked at $525K in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • PSP Research held 4,000 shares of Kymera Therapeutics worth $459K as of Q2 2026.
  • PSP Research sold 2,300 Kymera Therapeutics shares in Q2 2026, an estimated $198K.
  • Kymera Therapeutics made up 0.24% of PSP Research's portfolio in Q2 2026, its #26 holding.
  • PSP Research first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Kymera Therapeutics position peaked at $525K in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.